U.S. markets open in 1 hour 46 minutes
  • S&P Futures

    3,887.00
    +19.50 (+0.50%)
     
  • Dow Futures

    31,544.00
    +186.00 (+0.59%)
     
  • Nasdaq Futures

    13,113.25
    +58.00 (+0.44%)
     
  • Russell 2000 Futures

    2,253.20
    +24.10 (+1.08%)
     
  • Crude Oil

    60.65
    +0.90 (+1.51%)
     
  • Gold

    1,722.80
    -10.80 (-0.62%)
     
  • Silver

    26.64
    -0.24 (-0.91%)
     
  • EUR/USD

    1.2071
    -0.0016 (-0.13%)
     
  • 10-Yr Bond

    1.4150
    0.0000 (0.00%)
     
  • Vix

    22.95
    -0.40 (-1.71%)
     
  • GBP/USD

    1.3973
    +0.0017 (+0.12%)
     
  • USD/JPY

    106.9220
    +0.2120 (+0.20%)
     
  • BTC-USD

    52,019.70
    +2,981.34 (+6.08%)
     
  • CMC Crypto 200

    1,040.38
    +52.29 (+5.29%)
     
  • FTSE 100

    6,668.28
    +54.53 (+0.82%)
     
  • Nikkei 225

    29,559.10
    +150.93 (+0.51%)
     

Qiagen reports Q4 beat on added boost from non-COVID-19 products

  • Oops!
    Something went wrong.
    Please try again later.
·1 min read
  • Oops!
    Something went wrong.
    Please try again later.

Feb 9 (Reuters) - U.S.-German genetic testing specialistQiagen reported better-than-expected quarterly earningson Tuesday, citing very strong demand for COVID-19 testingcombined with improvements in non-COVID-19 areas of itsportfolio.

Qiagen said fourth-quarter net sales rose 36% to $571.2million on a currency-adjusted basis, beating the $539.14million expected on average by analysts in a Vara Research poll,as improved trends for its QuantiFERON tuberculosis test, cancerdiagnostics and DNA sample technologies complementedcoronavirus-related sales.

The company confirmed its guidance for 2021 adjusted EPS andnet sales growth.(Reporting by Zuzanna Szymanska in GdanskEditing by Chris Reese)